Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

4.9k

US$21.53

68.7% değerinin altında

stuart_roberts's

Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

Merck & Co., Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Merck
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$118.50
52 Haftanın En Yüksek Seviyesi	US$0
52 Haftanın En Düşük Seviyesi	US$0
Beta	0.26
1 Aylık Değişim	0%
3 Aylık Değişim	46.66%
1 Yıllık Değişim	-70.38%
3 Yıllık Değişim	-70.38%
5 Yıllık Değişim	43.46%
Halka arzdan bu yana değişim	200.76%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	MRK	CH Pharmaceuticals	CH Pazar
7D	0%	-5.1%	-3.7%
1Y	-70.4%	9.8%	-4.6%

Getiri vs. Endüstri: MRK geçen yıl % 9.8 oranında getiri sağlayan Swiss Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: MRK geçen yıl % -4.6 oranında getiri sağlayan Swiss Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	4.5%
Market Average Movement	4.2%
10% most volatile stocks in CH Market	7.8%
10% least volatile stocks in CH Market	2.3%

İstikrarlı Hisse Senedi Fiyatı: MRK hisse senedi fiyatı, son 3 ayda Swiss piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: MRK 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1891	74,000	Rob Davis	www.merck.com

Merck & Co., Inc. dünya çapında bir sağlık şirketi olarak faaliyet göstermektedir. İlaç ve Hayvan Sağlığı olmak üzere iki segmentte faaliyet göstermektedir. Şirket, Keytruda, Welireg, Gardasil, ProQuad adı altında onkoloji, aşılar, hastane akut bakımı, kardiyovasküler, viroloji, nörobilim ve diyabet dahil olmak üzere çeşitli alanlar için insan sağlığı ilaçları sunmaktadır, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia ve Janumet markaları.

Merck & Co., Inc. Temel Bilgiler Özeti

Merck'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MRK temel i̇stati̇sti̇kler
Piyasa değeri	CHF 222.54b
Kazançlar(TTM)	CHF 14.39b
Gelir(TTM)	CHF 51.25b

15.5x

F/K Oranı

4.3x

P/S Oranı

MRK aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MRK gelir tablosu (TTM)
Gelir	US$65.01b
Gelir Maliyeti	US$14.82b
Brüt Kâr	US$50.20b
Diğer Giderler	US$31.94b
Kazançlar	US$18.25b

Son Raporlanan Kazançlar

Dec 31, 2025

Sonraki Kazanç Tarihi

Apr 30, 2026

Hisse başına kazanç (EPS)	7.38
Brüt Marj	77.21%
Net Kâr Marjı	28.08%
Borç/Özkaynak Oranı	93.7%

MRK uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

3.0%

Mevcut Temettü Verimi

44%

Ödeme Oranı

MRK güvenilir bir temettü ödüyor mu?

MRK temettü geçmişine ve kıyaslamalara bakın

Yaklaşan bir temettüyü almak için ne zaman MRK satın almanız gerekir?
Merck temettü tari̇hleri̇
Eski Temettü Tarihi	Mar 16 2026
Temettü Ödeme Tarihi	Apr 07 2026
Eski temettüye kadar geçen günler	7 days
Temettü ödeme tarihine kadar geçen günler	15 days

MRK güvenilir bir temettü ödüyor mu?

MRK temettü geçmişine ve kıyaslamalara bakın

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/03/22 22:27
Gün Sonu Hisse Fiyatı	2026/02/13 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza ilişkin kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Merck & Co., Inc. 50 Bu analistlerden 22, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Toung	Argus Research Company
Emily Field	Barclays
Charles Butler	Barclays

Merck (MRK) Hisse Özeti

Ödüller

Risk Analizi

Looking to be second time lucky with a game-changing new product

Merck & Co., Inc. Rakipler

Novartis

Roche Holding

Roche Holding

Galderma Group

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Merck Presents New Data Reinforcing Long-Term Efficacy of Gardasil 9 and Gardasil At Eurogin International Multidisciplinary HPV Congress 2026

Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda

Merck & Co., Inc. Announces KEYTRUDA®? (Pembrolizumab) Plus Padcev®? (enfortumab Vedotin-Ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Ejfv

Merck & Co., Inc. Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL) an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Merck & Co., Inc. Announces Executive Appointments and Organizational Changes in Human Health Business

Merck Announces Positive New Data for ENFLONSIA (Caresrovimab) for Infants and Children Under 2 Years of Age At Increased Risk for Severe Respiratory Syncytial Virus Disease over Two RSV Seasons

Recent updates

Merck Presents New Data Reinforcing Long-Term Efficacy of Gardasil 9 and Gardasil At Eurogin International Multidisciplinary HPV Congress 2026

Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda

Merck & Co., Inc. Announces KEYTRUDA®? (Pembrolizumab) Plus Padcev®? (enfortumab Vedotin-Ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Ejfv

Merck & Co., Inc. Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL) an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Merck & Co., Inc. Announces Executive Appointments and Organizational Changes in Human Health Business

Merck Announces Positive New Data for ENFLONSIA (Caresrovimab) for Infants and Children Under 2 Years of Age At Increased Risk for Severe Respiratory Syncytial Virus Disease over Two RSV Seasons

Merck announces Health Canada Approves KEYTRUDA SC™, a Subcutaneous Formulation of Pembrolizumab Across Multiple Cancer Indications

Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium

Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX

Merck Announces Health Canada Approval of ENFLONSIA for the Prevention of RSV in Newborns and Infants

Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2026

Merck Declares Dividend on Common Stock for the Second-Quarter of 2026, Payable on April 7, 2026

MSD Reportedly Ends Takeover Talks with Revolution Medicines

Merck Reportedly in Talks to Buy Revolution in Up to $32 Billion Deal

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib in Combination with KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph) in Certain Patients with Advanced NSCLC

Merck Reaches Agreement with U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Merck Announces KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Merck Receives Positive EU Chmp Opinion for Expanded Use of Winrevair™? (Sotatercept) in Adults with Pulmonary Arterial Hypertension (Pah, Who* Group 1 Pulmonary Hypertension)

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

FDA Approves Merck and KEYTRUDA (Pembrolizumab) and KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravir (Dor/Isl) in Treatment-1 Infection

Merck Declares Dividend for the First Quarter of 2026, Payable on January 8, 2026

Merck Reportedly Close on A Deal to Buy Cidara

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Adults with Heterozygous Familial Hypercholesterolemia in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Phase 3 CORALreef Lipids Trial

Merck & Co., Inc. Updates Earnings Guidance for the Year 2025

European Commission Approves KEYTRUDA® (Pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Merck Announces Positive Topline Results from the Phase 3 LITESPARK-022 Trial in Patients with Clear Cell Renal Cell Carcinoma

Merck & Co., Inc. Receives FDA Approval For Updated Indication Of WINREVAIR In Adults With PAH

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio At AHA Scientific Sessions 2025

Merck & Co., Inc. Announces the Presentation of Findings from Systematic Review of Studies on the Ep Epiiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CapvaXIVE

Merck & Co., Inc. Announces New Long-Term Data Highlighting the Sustained Survival Benefits of Keytruda® (Pembrolizumab), Merck’s anti-PD-1 Therapy, in Treating Non-Small Cell Lung Cancer (NSCLC )

Daiichi Sankyo and Merck Demonstrate Clinically Meaningful Response Rates for Raludotatug Deruxtecan in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Merck and Eisai Announces Long-Term Follow-Up Data Continued to Show Durable Benefit of KEYTRUDA®? (Pembrolizumab) Plus LENVIMA®? (lenvatinib)

Merck & Co., Inc. Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients with Platinum-Resistant Recurrent Ovarian Cancer

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravir/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Early Stages of Disease At ESMO 2025

Merck Expands Tulisokibart Clinical Development Program with Initiation of Phase 2B Trials in Three Additional Immune-Mediated Inflammatory Diseases

Merck Announces Positive Results from the Phase 3 HYPERION Trial Evaluating Winrevair

FDA Approves Merck’s KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA (pembrolizumab)

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

Merck & Co., Inc. Announces Positive Results from the Phase 3 STRIDE-13 Trial Evaluating CapvaXIVE

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Merck & Co., Inc. Announces Positive Topline Results from the Phase 3 CORALreef Lipids Trial Evaluating the Safety and Efficacy of Enlicitide Decanoate

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Health Canada Approves KEYTRUDA for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours That Are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined with Radiotherapy with or Without Cisplatin Then as Monotherapy

Merck Announces Positive Topline Results from the Phase 3 KEYTRUDA Trial in Patients with Muscle-Invasive Bladder Cancer

Merck & Co., Inc. Updates Sales Guidance for the Year 2025

Merck Declares Fourth-Quarter 2025 Dividend, Payable on October 7, 2025

Merck & Co., Inc. to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

FDA Grants Priority Review for WinrevaIR (sotatercept-csrk) to Update Label Based on Results from Zenith Trial of Merck & Co., Inc

Merck & Co., Inc.(NYSE:MRK) dropped from Russell 1000 Dynamic Index

Acip Recommends Use of Merck's Enflonsia for Prevention of Respiratory Syncytial Virus

Merck Announces Phase 3 HYPERION Study of Winrevair Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)

Merck Manuals Launches AI-Powered Search Tool, Providing Enhanced Access to Trusted Medical Information and Resources

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

FDA Approves Merck's Anti-PD-1 Therapy